Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator

Europace

Volumn 9, Issue 5, 2007, Pages 278-280

  Rudzinski, Tomasz ^a   Ciesielczyk, Michal ^a   Religa, Wojciech ^a   Bednarkiewicz, Zbigniew ^a   Krzeminska Pakula, Maria ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Anthracyclines; Arrhythmia; Cardiotoxicity

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CANCER STAGING; CARDIOVERSION; CASE REPORT; DEFIBRILLATION; DEFIBRILLATOR; DRUG PULSE THERAPY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART ARREST; HEART CATHETERIZATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MASTECTOMY; PRIORITY JOURNAL; SINUS RHYTHM;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DEFIBRILLATORS, IMPLANTABLE; DOXORUBICIN; FEMALE; HUMANS; MIDDLE AGED; RECURRENCE; TACHYCARDIA, VENTRICULAR;

EID: 34447551686     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eum033     Document Type: Article

References (17)

1. Shan K, Lincoff AM, Young JB. Anthracycline induced cardiotoxicity. Ann Intern Med 1996;125:47-58.
2. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001;344:1997-2008.
3. Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, Ross AM. Acute arrhythmogenicity of doxorubicin administration. Cancer 1987;60 1213-18.
4. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozencweig M et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.
5. Hayek ER, Speakman E. Rehmus E. Acute doxorubicin cardiotoxicity. N Engl J Med 2005;352:2456-7.
6. Kilickap S, Akgul E, Aksoy S, Aytemir K, Barista I. Doxorubicin-induced second degree and complete atrioventricular block. Europace 2005; 7:227-30.
7. O'Bryan RM, Luce JK, Talley, Gottlieb JA, Baker LH, Bonnadonna G. Phase II evaluation of adriamycin in human neoplasis. Cancer 1973;32 1-8.
8. Wortman JE, Lucas VS, Schuster E, Thiele D, Logue TL. Sudden death during doxorubicin administration. Cancer 1979;44:1588-91.
9. Couch RD, Loh KK, Sugino J. Sudden cardiac death following adriamycin therapy. Cancer 1981;48:38-9.
10. Lacasse Y, Bolduc P. Sudden death in leukemic patients treated with doxorubicin. Can J Cordiol 1992;8:53-6.
11. Friess GG, Boyd JF, Geer MR, Garcia JC. Effects of first-dose doxorubicin on cardiac rhythm as evaluated by continuous 24-hour monitoring. Cancer 1985;56:2762-4.
12. Raabe NK, Storstein L. Cardiac arrhythmias in patients with small cell lung cancer and cardiac disease before, during and after doxorubicin administration. An evaluation of acute cardiotoxicity by continuous 24-hour Holter monitoring. Acta Oncol 1991;30:843-6.
13. Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992;70:73-7.
14. Rajagopalan S, Politi PM, Sinha BK, Myers CE. Adriamycin-induced free radical formation in the perfused rat heart: Implications for cardiotoxicity. Cancer Res 1988;48:4766-9.
15. Bristow MR, Kantrowitz NE, Harrison WD, Minobe WA, Sageman WS, Bittingham ME et al. Mediation of subacute anthracycline cardiotoxicity in rabbits by cardiac histamine release. J Cardiovasc Pharmacol 1983;5:913-9.
16. Wang YX, Korth M. Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium. Circ Res 1995;76 645-53.
17. Valdes Olmos RA, ten Bokkel Huinink WW, ten Koeve RF, van Tinteren H, Bruning PF, van Vlies B et al. Assessment of anthracycline-related myocardial adrenergic derangement by (1231)metaiodobenzylguanidine scintigraphy. Eur J Cancer 1995;31A:26-31.